source
- Novartis secures supplemental FDA approval to market repurposed antibiotic Lamprene in the USNovartis has obtained a supplemental approval from the U.S. Food and Drug Administration for its drug Lamprene, allowing it to be sold as an antibiotic. Lamprene, originally developed decades ago…
- BioNTech's mRNA cancer therapy fails to improve progression-free survival in head-neck cancer trialBioNTech reported that its experimental mRNA cancer immunotherapy, BNT 113, combined with Keytruda, did not meet the primary endpoint of progression-free survival in an interim analysis of a late-s…